Ultomiris Gets US Accelerated Approval In IgA Nephropathy On A 43.4% Proteinuria Reduction

The approval rests on a lab marker, not proof of slower kidney decline, and kidney-function data from the I CAN trial are still pending.

Share
Ultomiris Gets US Accelerated Approval In IgA Nephropathy On A 43.4% Proteinuria Reduction

AstraZeneca's Alexion unit won US accelerated approval for Ultomiris in adults with IgA nephropathy, a rare kidney disease, the company said in a statement dated Thursday and furnished to the SEC on Form 6-K. The drug showed a placebo-adjusted 43.4% reduction in proteinuria (protein in the urine) at 34 weeks in an interim trial analysis.

What the approval covers

The US Food and Drug Administration approved Ultomiris (ravulizumab) to reduce proteinuria in adults with primary immunoglobulin A nephropathy who are at risk of disease progression. The company calls it the first and only C5 complement inhibitor approved for that use.

Accelerated approval means the FDA cleared the drug on a surrogate measure. The company said it has not been established whether Ultomiris slows kidney function decline, and continued approval may depend on the ongoing I CAN late-stage trial verifying clinical benefit.

The approval followed Priority Review by the FDA. Ultomiris is given intravenously every eight weeks after a loading dose, with dosing based on body weight.

The trial numbers

In the prespecified interim analysis of the placebo-controlled I CAN trial, patients on Ultomiris had a 46.6% reduction in 24-hour urine protein creatinine ratio from baseline at week 34. Patients on placebo had 5.6%. That gives the placebo-adjusted effect of 43.4% (95% confidence interval 33.5% to 51.8%; p<0.0001).

The reduction showed as early as week 10, at 36.7% with Ultomiris versus 8.5% with placebo. The company said results were consistent across patient subgroups.

The company said safety matched the known profile of Ultomiris, with no new concerns. The most common adverse events on Ultomiris were upper respiratory tract infection (11.3%), nasopharyngitis (9.2%) and infusion-related reactions (8.4%). On placebo they were upper respiratory tract infection (10.2%), nasopharyngitis (9.0%) and hypertension (6.6%).

What it changes and what comes next

Alexion CEO Marc Dunoyer said the approval "marks the fifth indication for Ultomiris." Richard Lafayette, a Stanford professor of medicine and co-chair of the trial's external scientific committee, said physicians now have a C5 inhibitor for reducing proteinuria in a progressive disease.

The company said IgAN affects more than 200,000 people in the US. Regulatory submissions based on the interim results are under review in Japan and additional countries.

The trial's primary kidney-function endpoint, change in estimated glomerular filtration rate at week 106, is still being assessed, and the company said that data are intended to support traditional FDA approval. Late-breaking results will be presented at the American Society of Nephrology's Kidney Week on 23 October 2026.

The next data point is Friday's Kidney Week presentation; the one that decides whether the approval becomes a traditional one is the week-106 kidney-function readout.

Sources